LON:SVNS Solvonis Therapeutics (SVNS) Share Price, News & Analysis GBX 0.15 0.00 (0.00%) As of 12:03 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartEarningsBuy This Stock About Solvonis Therapeutics Stock (LON:SVNS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Solvonis Therapeutics alerts:Sign Up Key Stats Today's Range 0.15▼ 0.1650-Day Range 0.13▼ 0.2252-Week Range 0.12▼ 0.40Volume11.95 million shsAverage Volume33.12 million shsMarket Capitalization£10.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company headquartered in the United Kingdom. The company is developing a proprietary synthetic exosome platform designed to enhance the targeted delivery of therapeutic compounds. By engineering nanoscale vesicles that mimic natural exosomes, Solvonis aims to improve tissue selectivity, increase payload stability and enable efficient transport of small molecules, peptides and nucleic acids across biological barriers. The company’s lead programs focus on oncology and central nervous system disorders, where delivery challenges have historically limited the efficacy of novel therapeutics. Solvonis’ modular vesicle system can be customized to carry a range of payloads and surface ligands, allowing for precision targeting of solid tumours or neural tissues. Preclinical studies are ongoing to assess safety, biodistribution and therapeutic activity in relevant disease models. Solvonis collaborates with academic institutions and contract research organizations to advance its pipeline through preclinical development. With operations centred in the UK and strategic partnerships in place, the company is positioning its synthetic exosome technology as a next-generation delivery solution for the global biopharmaceutical industry.AI Generated. May Contain Errors. Read More Receive SVNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Solvonis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SVNS Stock News HeadlinesSolvonis’ SVN-015 Cleared for Further NIDA Studies in Stimulant Use DisorderAugust 6, 2026 | tipranks.comSolvonis advances esketamine thin-film AUD therapy with positive U.S. bridge dataJune 22, 2026 | tipranks.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 17 at 1:00 AM | Banyan Hill Publishing (Ad)Solvonis Wins Shareholder Backing as It Advances CNS Drug PipelineJune 19, 2026 | tipranks.comSolvonis pivots strategy to carry lead AUD drug through Phase 3 amid sector tailwindsApril 29, 2026 | tipranks.comSolvonis wins second U.S. patent to deepen PTSD therapy IPApril 8, 2026 | tipranks.comSolvonis Extends Novel SDRI SVN‑015 Into Depression After Positive Preclinical ResultsJanuary 28, 2026 | tipranks.comSolvonis’ SVN-015 Accepted into NIDA Program for Addiction TreatmentDecember 3, 2025 | tipranks.comSee More Headlines SVNS Stock Analysis - Frequently Asked Questions How have SVNS shares performed this year? Solvonis Therapeutics' stock was trading at GBX 0.31 at the start of the year. Since then, SVNS stock has decreased by 51.6% and is now trading at GBX 0.15. How were Solvonis Therapeutics' earnings last quarter? Solvonis Therapeutics (LON:SVNS) released its quarterly earnings data on Wednesday, April, 29th. The company reported ($0.12) EPS for the quarter. How do I buy shares of Solvonis Therapeutics? Shares of SVNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings4/29/2026Today8/17/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorN/A Industry N/A Sub-IndustryN/A Current SymbolLON:SVNS CIKN/A WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares6,806,403,000Free FloatN/AMarket Cap£10.21 million OptionableN/A BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (LON:SVNS) was last updated on 8/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solvonis Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Solvonis Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
